Journal of Cancer Research and Clinical Oncology最新文献

{"title":"LncRNA LINC01128 promotes prostate cancer cell proliferation, metastasis, and epithelial-mesenchymal transition by modulating miR-27b-3p.","authors":"Yuhui Zhao, Zhihang Zhang, Yi Zheng, Huiming Bai, Xiaotong Wu, Yantao Yang, Junfeng Zhang, Chao Yu","doi":"10.1007/s00432-025-06153-6","DOIUrl":"10.1007/s00432-025-06153-6","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is a prevalent malignancy within the male reproductive system that poses a significant threat to patients' lives. The function of long non-coding RNA LINC01128 in PCa progression remains to be elucidated.</p><p><strong>Objective: </strong>The objective was to evaluate the significance of LINC01128 in PCa and to elucidate the underlying mechanisms, thereby identifying a potential target for PCa treatment.</p><p><strong>Methods: </strong>The clinical significance of LINC01128 in PCa was investigated by bioinformatics methods and data analysis. The expression of LINC01128 was quantified using real-time quantitative PCR. The impact of LINC01128 on PCa cell viability and metastasis was evaluated through Cell Counting Kit-8 and Transwell assays. The expression of epithelial-mesenchymal transition markers was analyzed by Western blot analysis. Bioinformatics methods and dual-luciferase reporter assay were employed to explore the mechanisms underlying the role of LINC01128 in PCa progression.</p><p><strong>Results: </strong>LINC01128 demonstrated significant upregulation in PCa and exhibited a strong correlation with tumor-node-metastasis (TNM) stage, Gleason score, and lymph node metastasis. The upregulation of LINC01128 was found to be linked to a poorer prognosis for PCa. In PCa cells, silencing LINC01128 resulted in the suppression of cell proliferation, migration, and invasion. Furthermore, the knockdown of LINC01128 enhanced the expression of E-cadherin while concurrently repressing the expression of N-cadherin and Vimentin. Mechanistically, the negative regulation of miR-27b-3p by LINC01128 mediated the role of LINC01128 in PCa progression.</p><p><strong>Conclusions: </strong>In PCa, high expression of LINC01128 may predict patients' unfavorable prognosis. LINC01128 promoted PCa cellular processes by negatively regulating miR-27b-3p.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"98"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of prognosis and related influencing factors of different surgical approaches for early cervical cancer.","authors":"Lingling Ou, Lulu He, Qiaowen Bu, Hengying Wu, Bin Wen, Xiping Luo, Xiaoshan Hong","doi":"10.1007/s00432-025-06139-4","DOIUrl":"10.1007/s00432-025-06139-4","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the 5-year survival rates of patients with early cervical cancer (CC) under different surgical approaches and to analyze the factors affecting the prognosis of these patients.</p><p><strong>Methods: </strong>A retrospective analysis and follow-up study were conducted on patients who underwent surgical treatment for early CC at Guangdong Women and Children Hospital between January 2005 and December 2017. Prognostic factors were analyzed using the Kaplan-Meier method and Cox regression model.</p><p><strong>Results: </strong>A total of 726 patients were included, with 347 in the open surgery group and 379 in the laparoscopy group. The proportion of deep stromal infiltration in the open group was significantly higher than in the laparoscopy group (228/347 vs. 194/379, respectively; P < 0.05). Similarly, the tumor diameter (< 4 cm) was significantly larger in the open group compared to the laparoscopy group (51/347 vs. 26/379, respectively; P < 0.05). There were no statistically significant differences between the two groups in terms of the number of pregnancies, number of deliveries, menopause, contraceptive methods, high-risk HPV infection, clinical stage, pathological type, degree of differentiation, parametrial invasion, or lymph node metastasis (P > 0.05). The mean follow-up period was 53.15 ± 15.33 months. The overall 5-year survival rate (OS) for all patients was 89.0%, while the disease-free survival rate (DFS) was 86.8%. The 5-year OS rates in the open and laparoscopy groups were 87.2% and 90.4%, respectively, while the 5-year DFS rates were 84.6% and 88.6%, respectively, with no statistically significant differences between the groups (P > 0.05). Multivariate analysis revealed that clinical stage, vascular invasion, and tumor diameter were independent risk factors affecting survival and prognosis in patients with CC. However, the surgical approach did not significantly influence prognosis.</p><p><strong>Conclusion: </strong>The 5-year overall survival rate of patients with early CC was 89.0%. Laparoscopic surgery did not adversely affect the prognosis of early CC patients. Both surgical approaches demonstrate favorable prospects for treating early CC. Prognosis in early CC is influenced by clinical stage, vascular invasion, and tumor diameter, rather than the surgical approach used.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"97"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CENPF as a prognostic marker of glioma: unraveling the molecular mechanisms.","authors":"Xiuyang Chen, Yiwei Wu, Yining Xing, Peng Zhong","doi":"10.1007/s00432-025-06144-7","DOIUrl":"10.1007/s00432-025-06144-7","url":null,"abstract":"<p><strong>Objective: </strong>Glioma is the dominant primary intracranial malignancy. The roles of CENPF and the CENPF - p53 axis in glioma remain elusive. This study uses bioinformatics and animal experiments to clarify the relationship between CENPF and p53 in glioma. CENPF affects spindle assembly and chromosomal segregation, while p53 is a tumor-suppressor gene. Their dysregulation may interact and impact glioma development. Our research aims to uncover the underlying molecular mechanisms, offering new perspectives for glioma diagnosis and treatment.</p><p><strong>Method: </strong>Gene expression data from the Gene Expression Omnibus (GEO) database ( http://www.ncbi.nlm.nih.gov/geo/ ) were retrieved, specifically datasets GSE50161, GSE104291, and GSE12249. Volcano plots were generated to visualize differentially expressed genes (DEGs), and intersecting DEGs were identified using Venn diagrams. Weighted gene co-expression network analysis (WGCNA) was employed to construct and analyze the protein-protein interaction (PPI) network. Additionally, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted. Gene set enrichment analysis (GSEA) was utilized for comprehensive GO and KEGG analyses of the entire genome. Comparative Toxicogenomics Database (CTD) analysis was performed, and TargetScan was used to identify miRNAs regulating central DEGs. An animal model of glioma was established and analyzed via Western blot.</p><p><strong>Result: </strong>A total of 501 differentially expressed genes (DEGs) were identified, from which eight significant modules were generated and ten core genes were extracted. These core genes exhibited differential expression patterns between glioma tumor and non-tumor samples. Expression analysis revealed that the ten core genes associated with glioma (CENPF, PBK, ASPM, KIF2C, KIF20A, CDC20, TOP2A, NUSAP1, TTK, KIF23) were significantly upregulated in tumor tissues (P < 0.05). They are primarily enriched in protein signal transduction, coated membrane structures, AP-type membrane coat adaptor complexes, and chloride channel activity. KEGG pathway analysis indicated that these target genes were mainly involved in nicotine addiction, arginine and proline metabolism, beta-alanine metabolism, and histidine metabolism. The mouse model confirmed that CENPF and CDK-1 were highly expressed in glioma tissues, while p53, p21, and Caspase9 were downregulated, leading to inhibition of the apoptosis pathway and exacerbation of glioma progression. Overexpression of CENPF further suppressed key molecules in the p53-mediated apoptosis pathway. Conversely, low expression of CENPF activated these key molecules, inducing apoptosis in glioma cells.</p><p><strong>Conclusions: </strong>CENPF exhibits elevated expression levels in glioma, potentially inhibiting cell apoptosis via the p53 signaling pathway, consequently contributing to the onset and progression of glioma.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"96"},"PeriodicalIF":2.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-related disparities in outcomes of survival in biliary tract cancer patients.","authors":"Nadiye Sever, Emil Yunusov, Nargiz Majidova, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Abdussamet Çelebi, Selver Işık, İbrahim Vedat Bayoğlu, Osman Köstek, Murat Sarı","doi":"10.1007/s00432-025-06096-y","DOIUrl":"10.1007/s00432-025-06096-y","url":null,"abstract":"<p><strong>Introduction: </strong>Biliary tract cancer (BTC) is a rare and aggressive cancer with a poor prognosis. Despite treatment, overall survival is less than 12 months. It is a proven fact that women have better chemotherapy responses and survival than men in almost all cancer types. We believe that gender is one of the important factors affecting the prognosis of BTC. In this study, we aimed to investigate the effect of gender on prognosis in this type of cancer.</p><p><strong>Methods: </strong>This study was designed as a single-centre retrospective analysis of patients with BTC. All patients, regardless of operability, were included in the study. Prognostic factors were analysed using univariate and multivariate analysis.</p><p><strong>Results: </strong>A total of 100 patients (48% female) were included in the study. The median follow-up time was 72.2 months (95% CI 39.3-105.0), and the median OS was 9.5 months (95% CI 5.3-13.8) for all study patients. The 72-month survival rate was 13.4%. The observed survival rates at 10.4% for male patients and 15.7% for female patients demonstrate the importance of considering gender as a prognostic factor. A multivariate analysis indicated a significant association between female gender and longer overall survival, with an adjusted hazard ratio of 0.59 (95% CI 0.38-0.92, p = 0.02).</p><p><strong>Conclusion: </strong>It is clear that female gender is associated with a better response to chemotherapy and longer survival in BTCs. These findings should be taken into account in treatment selection and prognosis predictions. Further research may help elucidate the mechanisms underlying these sex differences and help develop more effective treatments.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"95"},"PeriodicalIF":2.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China.","authors":"Liyuan Wu, Wei Rao, Lei Guo, Fanshuang Zhang, Weihua Li, Jianming Ying","doi":"10.1007/s00432-025-06118-9","DOIUrl":"10.1007/s00432-025-06118-9","url":null,"abstract":"<p><strong>Purpose: </strong>The Kirsten rat sarcoma viral oncogene (KRAS) is the most frequently mutated oncogene in human cancers. Significant advancements have been made in targeted therapy and immunotherapy for this gene in recent years, underscoring the importance of comprehensively understanding the genomic landscape of KRAS across various cancer types.</p><p><strong>Methods: </strong>Using next-generation sequencing (NGS) technology and a panel of 520 genes, KRAS mutations, tumor mutation burden (TMB), and microsatellite instability (MSI-H) status were investigated.</p><p><strong>Results: </strong>An analysis of 10,820 tumor samples found KRAS mutations in 19.97% of cases. Pancreatic cancer showed the highest prevalence of KRAS mutations at 73.51%, while colorectal at 41.45%, uterine at 21.23%, and lung cancer at 11.24%. KRAS G12D mutation is most common in pancreatic, colorectal, and gastric cancers, while KRAS G12V mutation is predominant in uterine cancer, and KRAS G12C mutation is most frequent in lung cancer. Significant correlations were found between TMB and KRAS G13D/G12V mutations in colorectal cancer. KRAS G13D notably affected TMB in uterus cancer, while KRAS G12C mutation was linked to high TMB in lung cancer. Moreover, statistical analysis revealed a significant association between KRAS G13D/G12V mutations and MSI-H in colorectal cancer.</p><p><strong>Conclusions: </strong>KRAS mutations were most frequent in cancers of the digestive, female reproductive, and respiratory systems. Specific KRAS mutations are associated with TMB and MSI in various cancer types.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"94"},"PeriodicalIF":2.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclosporine plus methotrexate versus cyclosporine alone for graft-versus-host disease prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation from an HLA-identical sibling.","authors":"Vincenzo Apolito, Valeria Ceolin, Manuela Spadea, Raffaele Vitale, Marta Barone, Alessio Tomatis, Paola Quarello, Francesco Saglio, Franca Fagioli","doi":"10.1007/s00432-025-06138-5","DOIUrl":"10.1007/s00432-025-06138-5","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"91"},"PeriodicalIF":2.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁵⁷Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy.","authors":"Liang Xie, Jialin Qin, Cuiping Song, Jianchun Yin, Ruixue Wu, Hong Chen, Yujie Dong, Nianfei Wang, Lei Chen, Bing Hong, Ni Chen, Peng Lu, Fei Li, Xiaoxi Pang","doi":"10.1007/s00432-025-06136-7","DOIUrl":"10.1007/s00432-025-06136-7","url":null,"abstract":"<p><strong>Purpose: </strong>Gadolinium-neutron capture therapy (Gd-NCT) employs isotopically enriched Gadolinium (Gd) and thermal neutrons to selectively target cancer cells. This study investigated the targeting efficacy of ¹⁵⁷Gd-DOTA-PSMA (Prostate-Specific Membrane Antigen) in prostate cancer and explored its potential applications in Gd-NCT.</p><p><strong>Methods and results: </strong>We developed ¹⁵⁷Gd-DOTA-PSMA, a novel theranostic bio-gadolinium agent specifically designed for magnetic resonance imaging (MRI)-guided Gd-NCT. ⁶⁸ Ga-DOTA-PSMA positron emission tomography-computed tomography (PET/CT) imaging showed peak radiotracer uptake at 2 h post-injection, with a tumor-to-non-tumor (T/NT) ratio of 6.95 ± 0.60. MRI analysis confirmed a stable T₁ signal enhancement 2 h post-injection. Time-of-flight inductively coupled plasma mass spectrometry (TOF-ICP-MS) revealed significantly elevated Gd concentrations in 22Rv1 tumor compared to PC-3 tumor and other healthy organs. ICP-MS analysis showed Gd concentrations of 165.69 μg [Gd]/g in 22Rv1 tumors and 35.25 μg [Gd]/g in blood, yielding a tumor-to-blood (T/B) ratio of 4.65 ± 0.54 and a T/NT ratio of 3.65 ± 0.49. Neutron irradiation with ¹⁵⁷Gd-DOTA-PSMA reduced cell viability, inhibited colony formation, and induced DNA damage and apoptosis in 22Rv1 cells. In 22Rv1 mice, γ-H2AX levels peaked at 6 h post-irradiation, accompanied by an increase in pro-apoptotic proteins and a decrease in anti-apoptotic proteins over 24 h. In the NCT group following the injection of ¹⁵⁷Gd-DOTA-PSMA, there was effective suppression of tumor growth without a loss of body weight, resulting in a 1.7-fold increase in median survival compared to control group.</p><p><strong>Conclusions: </strong>¹⁵⁷Gd-DOTA-PSMA, as a theranostic bio-gadolinium agent designed for targeted Gd-NCT in prostate cancer, represents a novel therapeutic approach and broadens the scope of potential applications of neutron capture therapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"93"},"PeriodicalIF":2.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143501239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of folate-associated gene expression in stage II colon cancer.","authors":"Donia Kaidi, Elisabeth Odin, Yvonne Wettergren, Elinor Bexe Lindskog","doi":"10.1007/s00432-025-06141-w","DOIUrl":"10.1007/s00432-025-06141-w","url":null,"abstract":"<p><strong>Purpose: </strong>Prognostic variability in stage II colon cancer underscores the need for better risk stratification. Analyzing folate-associated gene expression in stage II colon cancer could provide researchers and clinicians with deeper insights into tumor biology and potentially aid in identifying early prognostic and/or predictive biomarkers.</p><p><strong>Methods: </strong>Patients with stage II colon cancer and recurrence (n = 48) were matched to patients with a 5 year recurrence-free follow-up (n = 133). Gene expression of ABCC3, AMT, FPGS, GGH, MFT, PCFT, RFC-1, and TYMS was analyzed in tumor tissue and matching colon mucosa using qPCR and evaluated in relation to time to recurrence (TTR), as well as to demographic and clinicopathological variables.</p><p><strong>Results: </strong>Independent of other covariates, TYMS expression in tumors, pT4 stage, and emergency surgery were associated with TTR. There were significant differences in expression levels of all examined genes between tumor and mucosa. ABCC3, GGH, and RFC-1 expression levels differed in mucosa between microsatellite instability-high (MSI-H) compared to microsatellite stable/microsatellite instability-low (MSS/MSI-L) tumors, whereas tumoral expression of AMT, GGH, and TYMS differed between MSI-H and MSS/MSI-L tumors. Depending on tumor location, the expression of ABCC3, AMT, GGH, and RFC-1 in mucosa, as well as the tumoral expression of AMT, GGH, PCFT and RFC-1 differed.</p><p><strong>Conclusion: </strong>Low tumoral expression of TYMS was associated with worse TTR, independent of MSI status, pT stage, and emergency surgery. The indication of a better outcome for patients with MSI-H status and high tumoral TYMS expression might be of particular interest in the stratification of patients for immunotherapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"92"},"PeriodicalIF":2.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Genetic inference and single cell expression analysis of potential targets in heart failure and breast cancer.","authors":"Yue Li, Ying Huang, Ning An, Xiaomiao Guan, Bing Liu, Huiying Li, Tingting Jiang","doi":"10.1007/s00432-025-06137-6","DOIUrl":"10.1007/s00432-025-06137-6","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"90"},"PeriodicalIF":2.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the COVID-19 pandemic and lockdown on cancer stage distribution and time to treatment initiation using cancer registry data of the Swiss cantons of Zurich and Zug from 2018 to 2021.","authors":"Flurina Suter, Miriam Wanner, Andreas Wicki, Dimitri Korol, Sabine Rohrmann","doi":"10.1007/s00432-025-06140-x","DOIUrl":"10.1007/s00432-025-06140-x","url":null,"abstract":"<p><strong>Purpose: </strong>Swiss healthcare institutions conducted only urgent procedures during the COVID-19 lockdown, potentially leading to a lack of care for other severe diseases, such as cancer. We examined the effects of the pandemic on cancer stage distribution and time between cancer diagnosis and treatment initiation using population-based cancer registry data.</p><p><strong>Methods: </strong>The study was based on data of the cancer registry of the cantons of Zurich and Zug from 2018 to 2021. Cancer stage distribution was analysed descriptively and with a Pearson's Chi-squared test. Time between cancer diagnosis and treatment initiation was determined in days and analysed descriptively and by fitting Quasipoisson regression models.</p><p><strong>Results: </strong>For all-cancer and colorectal, lung, and prostate cancer statistically significant evidence for a difference in cancer stages distribution among the incidence years was observed. Based on the all-cancer regression models, longer time to treatment initiation (TTI) was observed for patients diagnosed in 2021 and receiving surgery (Rate Ratio = 1.08 [95% confidence interval 1.03, 1.14]) or hormone therapy (1.20 [1.03, 1.40]) compared to those diagnosed in 2018/19 receiving those therapies. We observed no difference in TTI between cancer patients diagnosed in 2020 compared to 2018/19 for any of the therapies investigated, except for chemotherapy with shorter TTI (0.92 [0.86, 0.98]).</p><p><strong>Conclusion: </strong>The observed effects on cancer outcomes in 2020 and 2021 compared to 2018/19 coincided with the beginning of the COVID-19 pandemic in Switzerland in 2020 onwards. Short- and long-term effects of the pandemic on cancer outcomes and the public healthcare system were observed. However, we cannot exclude that the implementation of the new Swiss law on cancer registration in 2020 explains part of our observations.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"88"},"PeriodicalIF":2.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}